Sarilumab vs placebo or usual care
WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes WHO progression score (level 7 or above) D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 1.1 [0.9, 1.33]5 studies · 886 participantsVery low